Dr. Abhishek Tiwari

Consultant – Medical and Hemato Oncology

Area of Interest

• Breast Cancer Medical Management
• Chemotherapy for Breast Cancer
• Targeted Therapy for Breast Cancer
• Immunotherapy for Breast Cancer
• Hormone Therapy for Breast Cancer
• Systemic Breast Cancer Treatment
• Supportive and Palliative Breast Cancer Care

Request an Appointment

Brief Profile

Dr. Abhishek Tiwari is an experienced Medical Oncologist at Tender Palm Super Specialty Hospital in Lucknow, with over 8 years of oncology experience. He provides comprehensive medical oncology care for patients with breast cancer, with particular attention centered on personalized treatment planning, evidence-based systemic therapies, precision medicine, treatment response monitoring, and long-term patient management.

At the Center for Breast Cancer Treatment, Tender Palm Super Specialty Hospital, Dr. Tiwari's clinical role encompasses the medical management of breast cancer across its different stages—from newly diagnosed, early-stage breast cancer to locally advanced, recurrent, and metastatic disease.

His approach focuses on selecting the most appropriate treatment based on the biological characteristics of the tumor, disease stage, hormone receptor status, HER2 expression, molecular biomarkers, previous treatments, associated medical conditions, and individual patient preferences.

He works within a multidisciplinary breast cancer care model, co-ordinating with breast surgeons, surgical oncologists, radiation oncologists, radiologists, pathologists, reconstructive surgeons, and adjunctive care specialists to formulate individualized treatment strategies.

Dr. Tiwari's academic qualifications include an MBBS, an MD in Radiation Oncology, a DM in Medical Oncology, and the European Certification in Medical Oncology (ECMO). His professional experience includes appointments at AIIMS Bhubaneswar, Delhi State Cancer Hospital, and Regency Hospital, Kanpur. His clinical interests in immunotherapy, targeted therapy, and Precision Oncology are particularly relevant to the evolving treatment of breast cancer.

Areas of Expertise in Breast Cancer Treatment

1. Comprehensive Breast Cancer Evaluation, Diagnosis and Staging

Dr. Tiwari plays an important role in the diagnostic evaluation and clinical staging of patients with suspected or confirmed breast cancer.

His involvement includes reviewing clinical findings, imaging investigations, histopathology reports and molecular biomarker results to establish an appropriate systemic treatment strategy.

Key areas include:

• Clinical evaluation of newly diagnosed breast cancer and assessment of disease extent.
• Review of mammography, breast ultrasonography and breast MRI findings.
• Interpretation of core needle biopsy and histopathological reports.
• Evaluation of tumor grade, histological subtype and lymph node involvement.
• Assessment of estrogen receptor (ER), progesterone receptor (PR), HER2 and Ki-67 results.
• Recommendation and interpretation of HER2 confirmatory testing, where indicated.
• Evaluation of genetic testing, including BRCA1, BRCA2 and other hereditary cancer susceptibility genes in eligible patients.
• Selection of appropriate staging investigations, including CT, PET-CT or bone imaging when clinically indicated.
• Assessment of organ function, performance status and medical fitness before systemic treatment.
• Participation in multidisciplinary discussions to determine the optimal sequence of surgery, systemic therapy and radiotherapy.

His emphasis is on making sure that breast cancer treatment is guided not only by tumor size and stage but also by its underlying molecular and biological characteristics.

2. Neoadjuvant Chemotherapy – Breast Cancer Treatment Before Surgery

Dr. Tiwari is involved in planning and administering neoadjuvant systemic therapy for patients for whom preoperative treatment is clinically beneficial.

Neoadjuvant treatment may be recommended for selected patients with locally advanced breast cancer, triple-negative breast cancer, HER2-positive breast cancer, or other tumors where decreasing disease burden before surgery may improve treatment options.

His role includes:

• Choosing appropriate chemotherapy and targeted treatment regimens.
• Assessing eligibility for neoadjuvant treatment based on tumor subtype and stage.
• Planning anthracycline-based, taxane-based, or other evidence-supported chemotherapy regimens.
• Incorporating HER2-directed therapy in eligible HER2-positive breast cancers.
• Evaluating immunotherapy-based regimens for appropriate high-risk triple-negative breast cancer.
• Monitoring clinical and radiological response during treatment.
• Managing chemotherapy-related complications and treatment-related toxicities.
• Working with breast surgeons to determine the appropriate timing of surgery.
• Reviewing postoperative pathological response to guide further treatment.

A key objective of neoadjuvant therapy is to control the disease before surgery and, in suitable cases, improve the feasibility of breast-conserving surgery.

3. Adjuvant Chemotherapy – Treatment After Breast Cancer Surgery

Following breast cancer surgery, Dr. Tiwari evaluates the need for additional systemic treatment to reduce the risk of cancer recurrence.

Adjuvant treatment recommendations are individualized according to tumor stage, lymph node status, hormone receptor expression, HER2 status, pathological risk factors, and, where appropriate, genomic recurrence risk assessments.

His clinical responsibilities include:

• Evaluating the need for chemotherapy following lumpectomy or mastectomy.
• Selecting suitable postoperative chemotherapy regimens.
• Interpreting genomic assays, such as Oncotype DX, in appropriately selected patients.
• Planning adjuvant HER2-targeted treatment for eligible patients.
• Assessing indications for ongoing use of adjuvant immunotherapy or other escalation strategies following neoadjuvant therapy.
• Prescribing endocrine therapy for hormone receptor-positive breast cancer.
• Evaluating eligibility for additional targeted therapies in patients at elevated recurrence risk.
• Monitoring blood counts, liver and kidney function, cardiac function and treatment-related adverse effects.
• Coordinating the sequence of chemotherapy, radiotherapy, endocrine therapy and targeted treatment.

His aim is to minimize recurrence risk while preventing unnecessary treatment toxicity whenever clinically appropriate.

4. Targeted Therapy for HER2-Positive Breast Cancer

Dr. Tiwari's clinical interests in targeted therapies and precision oncology are especially relevant to the management of HER2-positive breast cancer.

HER2-positive breast cancers require carefully selected treatment strategies that target HER2-mediated cancer cell growth and signaling.

His role includes assessing eligibility, prescribing and monitoring appropriate HER2-directed systemic therapies, which may include:

• Trastuzumab-based treatment.
• Pertuzumab in combination with other indicated therapies.
• Trastuzumab emtansine (T-DM1) for selected patients.
• Trastuzumab deruxtecan in appropriate clinical settings.
• Other approved HER2-directed regimens based on disease stage, previous treatment, and current evidence.

He also evaluates cardiac function before and during therapies associated with potential cardiotoxicity, coordinates assessment of treatment response, and manages treatment-related complications.

The selection of a particular HER2-targeted medicine depends on the patient's disease stage, prior therapy, clinical eligibility, drug approval, and availability factors.

5. Immunotherapy for Triple-Negative Breast Cancer

Triple-negative breast cancer (TNBC) is an important area of modern medical oncology because it does not express estrogen receptors, progesterone receptors, or clinically positive HER2 status.

Dr. Tiwari's interest in immunotherapy-based cancer treatment supports his part in evaluating eligible patients with triple-negative breast cancer for contemporary systemic treatment approaches.

His responsibilities include:

• Assessing the stage and risk profile of triple-negative breast cancer.
• Evaluating eligibility for immune checkpoint inhibitor therapy.
• Reviewing PD-L1 testing when relevant to treatment selection.
• Planning chemotherapy and immunotherapy combinations for appropriate patients.
• Evaluating immunotherapy in selected high-risk early-stage or advanced triple-negative breast cancer.
• Monitoring for immune-related adverse events affecting the thyroid, lungs, liver, gastrointestinal tract and other organs.
• Managing treatment interruptions, toxicities and adjunctive medications.
• Assessing response and determining subsequent treatment strategies.

His approach stresses careful patient selection, evidence-based use of immunotherapy, and timely management of immune-related complications.

6. Hormonal and Endocrine Therapy for Breast Cancer

Hormone receptor-positive breast cancer (HR+) most of the time requires long-term endocrine treatment to reduce the risk of recurrence or control advanced disease.

Dr. Tiwari provides medical evaluation and management of endocrine treatment for eligible premenopausal and postmenopausal patients.

Treatment strategies may include:

• Tamoxifen.
• Aromatase inhibitors, including letrozole, anastrozole, and exemestane.
• Ovarian function suppression in selected premenopausal patients.
• Fulvestrant for appropriate advanced breast cancer settings.
• Endocrine therapy combined with CDK4/6 inhibitors.
• Selected newer endocrine agents based on molecular findings and clinical indications.

His responsibilities extend to supervising treatment compliance, menopausal symptoms, bone health, cardiovascular and metabolic risk factors, and other adverse effects associated with prolonged endocrine treatment.

He also evaluates the appropriate duration of endocrine therapy and discusses the potential positive effects and risks of extended treatment for patients at increased risk of recurrence.

7. Precision Oncology and Biomarker-Guided Breast Cancer Treatment

Precision oncology is increasingly important in breast cancer management, particularly when selecting therapies for recurrent, metastatic, or biologically high-risk disease.

Dr. Tiwari incorporates relevant molecular and pathological information into treatment planning to help identify patients who may benefit from specific targeted medicines.

His areas in clinical evaluation include:

• BRCA1 and BRCA2 mutation testing.
• Assessment of eligibility for PARP inhibitors in appropriate patients.
• PIK3CA mutation testing in selected advanced hormone receptor-positive breast cancers.
• ESR1 mutation assessment when clinically relevant.
• AKT pathway alterations and other actionable biomarkers.
• HER2-low and HER2-ultralow expression assessment in appropriate treatment settings.
• Next-generation sequencing (NGS) when results may influence clinical decisions.
• Interpretation of molecular reports and selection of suitable treatment options.

His objective is to identify treatment strategies matched to the patient's tumor biology rather than relying exclusively on conventional chemotherapy.

8. Management of Locally Advanced and Metastatic Breast Cancer

Dr. Tiwari provides medical oncology management for patients with locally advanced, recurrent, and metastatic breast cancer.

For patients with metastatic disease, the primary treatment goals often include controlling cancer progression, prolonging survival where possible, reducing symptoms, preserving organ function, and preserving quality of life.

His clinical role includes:

• Evaluating recurrent or metastatic disease.
• Reviewing biopsy and receptor reassessment when indicated.
• Selecting systemic treatment based on previous therapies and current tumor characteristics.
• Planning chemotherapy, endocrine therapy, immunotherapy, or targeted treatment.
• Evaluating the use of antibody-drug conjugates in eligible patients.
• Managing breast cancer with bone, liver, lung, or other metastatic involvement.
• Coordinating treatment for brain metastases with radiation oncology and neurosurgical specialists.
• Managing cancer-related pain, fatigue, appetite loss and other symptoms.
• Tracking treatment response through clinical evaluation, laboratory tests and appropriate imaging.
• Modifying treatment when disease progresses, or toxicity becomes unacceptable.

For patients with advanced breast cancer, he emphasizes continuity of care, realistic treatment goals, well-informed decision-making and symptom-directed supportive treatment.

9. Chemotherapy Administration and Treatment Safety

Safe administration and monitoring of systemic cancer treatment are central responsibilities of a medical oncologist.

Dr. Tiwari's role includes selecting treatment protocols, determining appropriate doses, assessing patient fitness, and supervising the clinical management of treatment-related complications.

Areas of care include:

• Individualized chemotherapy planning and dosing.
• Pretreatment evaluation and laboratory monitoring.
• Prevention and management of chemotherapy-induced nausea and vomiting.
• Assessment and management of neutropenia, anemia and thrombocytopenia.
• Prevention and management of febrile neutropenia.
• Management of chemotherapy-induced peripheral neuropathy.
• Assessment of mucositis, diarrhea, and dehydration.
• Monitoring for cardiotoxicity and other organ-specific adverse effects.
• Evaluation of treatment-related infections.
• Dose modification or treatment postponement when medically indicated.
• Counseling on medication adherence, infection precautions, and warning signs.

He also coordinates with nursing, pharmacy, nutrition, and auxiliary care teams to promote safe treatment delivery and timely recognition of complications.

10. Post-Treatment Breast Cancer Surveillance and Long-Term Follow-Up

Breast cancer care does not finish with completion of chemotherapy, surgery, or radiotherapy.

Dr. Tiwari's role comprises long-term follow-up and survivorship management, with emphasis on monitoring for recurrence, identifying late treatment-related complications, and supporting recovery.

Post-treatment care includes:

• Scheduled clinical follow-up and symptom assessment.
• Coordination of surveillance mammography and other imaging when indicated.
• Evaluation of new symptoms that may suggest recurrence.
• Monitoring long-term adverse effects of chemotherapy, endocrine therapy, and targeted therapy.
• Assessment of bone health and osteoporosis risk.
• Monitoring cardiac function in patients previously exposed to potentially cardiotoxic treatments.
• Management of menopausal symptoms and endocrine treatment-related complications.
• Evaluation of persistent fatigue, neuropathy and cognitive complaints.
• Support for medication adherence.
• Counseling regarding physical activity, nutrition, weight management and general health.
• Assessment of psychological distress, anxiety and fear of cancer recurrence.

Routine whole-body scans or tumor marker testing are not generally recommended for asymptomatic survivors of early-stage breast cancer unless clinically indicated.

His follow-up approach intends to maintain long-term health while preventing unnecessary investigations and interventions.

11. Management of Breast Cancer Recurrence

Patients experiencing local, regional or distant breast cancer recurrence require re-evaluation of their disease and treatment options.

Dr. Tiwari's role includes evaluating the site and extent of recurrence, reviewing previous treatments and coordinating additional diagnostic investigations.

Where appropriate, repeat biopsy and review of hormone receptors and HER2 status may help guide subsequent therapy.

Treatment may involve a mixture of systemic medicines, surgery, radiotherapy or symptom-directed interventions depending on the pattern of recurrence.

He works with the multidisciplinary breast cancer team to establish a personalized management plan that considers disease control, prior treatment exposure, expected benefits, possible adverse effects, and patient preferences.

12. Supportive Care and Management of Treatment-Related Complications

Dr. Tiwari's medical oncology responsibilities include addressing the physical complications plus supportive care needs that arise during breast cancer treatment.

Supportive care may involve:

• Management of cancer-related fatigue and weakness.
• Treatment of nausea, vomiting, and appetite disturbances.
• Evaluation and management of anemia and treatment-related cytopenias.
• Management of peripheral neuropathy.
• Support for chemotherapy-related hair loss and other visible treatment effects.
• Assessment of bone pain and skeletal complications.
• Management of endocrine therapy-related joint pain and menopausal symptoms.
• Nutritional assessment and referral for dietetic support.
• Psychological support and counseling referrals when required.
• Coordination of fertility preservation counseling before gonadotoxic treatment in eligible patients.
• Referral for rehabilitation, physiotherapy and lymphoedema management when indicated.

The aim is to improve treatment tolerance, minimize avoidable complications and help patients maintain their daily activities as far as possible.

13. Palliative Care for Advanced Breast Cancer

Palliative care is an essential element of comprehensive breast cancer management, particularly for patients with advanced or metastatic disease. It may be introduced alongside active cancer-directed treatment rather than being reserved exclusively for the final stages of illness.

Dr. Tiwari's role includes evaluating symptom burden, establishing realistic treatment objectives, and coordinating appropriate medical and palliative interventions.

Important aspects include:

Cancer Pain Management: Assessment and treatment of cancer-related pain using appropriate analgesics, including opioids when indicated, adjuvant medicines, and referral for specialized pain interventions.

Symptom Control: Management of breathlessness, nausea, vomiting, fatigue, constipation, appetite loss, insomnia, and other distressing symptoms.

Bone Metastasis Support: Assessment of skeletal complications and coordination of bone-modifying agents, palliative radiotherapy or orthopedic intervention once clinically indicated.

Management of Advanced Disease Complications: Medical assessment of malignant pleural effusion, hypercalcemia, spinal cord compression and other serious complications requiring urgent multidisciplinary intervention.

Psychological and Emotional Support: Helping patients and families address anxiety, distress, uncertainty plus the emotional impact of advanced cancer.

Goals-of-Care Discussions: Explaining the expected benefits, limitations and possible adverse effects of further systemic treatment to support well-informed decisions.

End-of-Life Care Coordination: When appropriate, collaborating with specialist palliative care teams to place priority on comfort, dignity, symptom relief and family support.

His palliative oncology approach focuses on preserving quality of life and aligning treatment decisions with each patient's clinical condition and personal priorities.

14. Breast Cancer Treatment Planning Through Multidisciplinary Coordination

Effective breast cancer management requires close coordination between medical oncology and other clinical disciplines.

At the Center for Breast Cancer Treatment, Dr. Tiwari contributes the medical oncology perspective to multidisciplinary treatment planning.

This includes coordination with:

• Breast and surgical oncologists team for operative planning and sequencing of systemic treatment.
• Radiation oncologists for postoperative or palliative radiotherapy decisions.
• Radiologists for disease staging, response assessment, and surveillance imaging.
• Pathologists for histopathological interpretation and biomarker evaluation.
• Plastic and reconstructive surgeons for coordinated treatment planning when breast reconstruction is considered.
• Genetic counselors for hereditary breast cancer risk assessment.
• Palliative care specialists for complex symptom management.
• Rehabilitation, nutrition and psychological support professionals for recovery and survivorship care.

This joint model intends to ensure that patients are given coordinated treatment across diagnosis, active therapy, follow-up and palliative care.

Patient-Centred Breast Cancer Care

Dr. Abhishek Tiwari's approach to breast cancer management combines contemporary systemic treatment strategies with individualized clinical decision-making.

He emphasizes explaining the diagnosis, available treatment options, predicted outcomes, possible adverse effects, and the importance of follow-up.

Treatment recommendations take into consideration not only the biological features of breast cancer but also the patient's age, menopausal status, associated illnesses, functional capacity, fertility considerations, treatment preferences and financial circumstances.

For patients requiring prolonged systemic treatment, he emphasizes continuity of care, timely management of adverse effects and regular review of treatment goals.

His focus is on delivering evidence-based, individualized and compassionate breast cancer care throughout the treatment journey.

Why Consult Dr. Abhishek Tiwari for Breast Cancer Treatment at Tender Palm Hospital?

Dr. Tiwari brings together advanced training in medical oncology, experience in systemic cancer treatment, and a clinical interest in precision medicine and immunotherapy.

Patients seeking breast cancer treatment may benefit from his expertise in evaluating and planning:

• Personalized chemotherapy before or after breast cancer surgery.
• HER2-directed targeted treatment.
• Immunotherapy for eligible triple-negative breast cancer.
• Hormonal treatment for hormone receptor-positive breast cancer.
• Biomarker-guided targeted therapy.
• Medical management of locally advanced, recurrent and metastatic breast cancer.
• Prevention and management of systemic treatment complications.
• Long-term endocrine therapy and survivorship follow-up.
• Symptom control, supportive oncology and palliative care.

His role at Tender Palm Super Specialty Hospital is centered on administering comprehensive medical oncology management that integrates modern cancer treatment with long-term patient care.

Professional Qualifications & Clinical Background

Certification in Advanced Management of Oncological Diseases from Harvard Medical School in 2025.